Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biologic response modifiers may be candidates for accelerated approval, FDA panel agrees.

Executive Summary

BIOLOGIC RESPONSE MODIFIERS MAY BE CANDIDATES FOR ACCELERATED APPROVAL based on response rates that show meaningful benefit over existing therapies, even though biologic responses may be slower than responses with traditional cytotoxic agents, FDA's Biological Response Modifiers Advisory Committee concluded Oct. 21. The FDA meeting was convened to discuss whether biologics are appropriate for accelerated approval even though they shrink tumors by different mechanisms of action from traditional cytotoxic agents.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel